Pursuit of a perfect insulin

Nature Reviews Drug Discovery

Volumn 15, Issue 6, 2016, Pages 425-439

  Zaykov, Alexander N ^a   Mayer, John P ^b   Dimarchi, Richard D ^a  

^a INDIANA UNIVERSITY   (United States)

^b Calibrium LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEPATOSELECTIVE INSULIN DERIVATIVE; INCRETIN; INSULIN; INSULIN DERIVATIVE; RECEPTOR ISOFORM SELECTIVE DERIVATIVE; RECOMBINANT DNA; SINGLE CHAIN INSULIN DERIVATIVE; ULTRA RAPID INSULIN DERIVATIVE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

DIABETES MELLITUS; DNA STRUCTURE; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; INTRAPULMONARY DRUG ADMINISTRATION; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANALYSIS; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84961227018     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.36     Document Type: Review

References (197)

1. Joslin, E. P., & Kahn, C. R. Joslin's Diabetes Mellitus (Lippincott Williams, & Wilkins, 2005
2. Goeddel, D. V., et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76, 106-110 (1979
3. Keefer, L. M., Piron, M. A., & De Meyts, P. Human insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptors. Proc. Natl Acad. Sci. USA 78, 1391-1395 (1981
4. Johnson, I. S. Human insulin from recombinant DNA technology. Science 219, 632-637 (1983
5. Lipska, K. J., et al. Use and out of pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA 311, 2331-2333 (2014
6. Hirsch, I. B. Insulin analogues. N. Engl. J. Med. 352, 174-183 (2005
7. Home, P., et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 37, 1499-1508 (2014
8. Cryer, P. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention (American Diabetes Association, 2012
9. Caparrotta, T. M., & Evans, M. PEGylated insulin Lispro, (LY2605541) - A new basal insulin analogue. Diabetes Obes. Metab. 16, 388-395 (2014
10. Gough, S. C. L., Harris, S., Woo, V., & Davies, M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes. Metab. 15, 301-309 (2013
11. Edgerton, D. S., et al. Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog. Diabetes 63, 3946-3954 (2014
12. Glendorf, T., et al. Engineering of insulin receptor isoform-selective insulin analogues. PloS ONE 6, e20288 (2011
13. Gough, S. C., et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26 week extension to a 26 week main trial. Diabetes Obes. Metab. 17, 965-973 (2015
14. Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinology 7, 385-395 (2011
15. Mo, R., Jiang, T., Di, J., Tai, W., & Gu, Z. Emerging micro-and nanotechnology based synthetic approaches for insulin delivery. Chem. Soc. Rev. 43, 3595-3629 (2014
16. Mayer, J. P., Zhang, F., & DiMarchi, R. D. Insulin structure and function. Biopolymers 88, 687-713 (2007
17. Romans, R. G., Scott, D. A., & Fisher, A. M. Preparation of crystalline insulin. Ind. Eng. Chem. 32, 908-910 (1940
18. Scott, D. A., & Best, C. H. The preparation of insulin. Ind. Eng. Chem. 17, 238-240 (1925
19. Hallas-Møller, K. K., Jersild, M. M., Petersen, K. K., & Schlichtkrull, J. J. Zinc insulin preparations for single daily injection: Clinical studies of new preparations with prolonged action. J. Am. Med. Assoc. 150, 1667-1671 (1952
20. Hallas-Møller, K. The lente insulins. Diabetes 5, 7-14 (1956
21. Patel, H. M., & Ryman, B. E. Oral administration of insulin by encapsulation within liposomes. FEBS Letters 62, 60-63 (1976
22. Best, C. The prolongation of insulin action. Ohio J. Science 37, 362-377 (1937
23. Fonte, P., Araújo, F., Reis, S., & Sarmento, B. Oral insulin delivery: how far are we? J. Diabetes Sci. Technol. 7, 520-531 (2013
24. Santos Cavaiola, T., & Edelman, S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin. Ther. 36, 1275-1289 (2014
25. Clarke, S., & Foster, J. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br. J. Biomed. Sci. 69, 83-93 (2012
26. Alsaleh, F., Smith, F., Keady, S., & Taylor, K. Insulin pumps: from inception to the present and toward the future. J. Clin. Pharm. Ther. 35, 127-138 (2010
27. Sanger, F., & Tuppy, H. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem. J. 49, 481 (1951
28. Sanger, F., & Tuppy, H. The amino-acid sequence in the phenylalanyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem. J. 49, 463 (1951
29. Bliss, M. Rewriting medical history: Charles Best and the Banting and Best myth. J. Hist. Med. Allied Sci. 48, 253-274 (1993
30. Katsoyannis, P. G., Fukuda, K., Tometsko, A., Suzuki, K., & Tilak, M. Insulin peptides. X. The synthesis of the B chain of insulin and its combination with natural or synthetis A chin to generate insulin activity. J. Am. Chem. Soc. 86, 930-932 (1964
31. Kung, Y. T., Du, Y., Huang, W., Chen, C., & Ke, L. Total synthesis of crystalline bovine insulin. Sci. Sin. 14, 1710 (1965
32. Marglin, B., & Merrifield, R. The synthesis of bovine insulin by the solid phase method1. J. Am. Chem. Soc. 88, 5051-5052 (1966
33. Ruttenberg, M. A. Human insulin: facile synthesis by modification of porcine insulin. Science 177, 623-626 (1972
34. Thim, L., et al. Secretion and processing of insulin precursors in yeast. Proc. Natl Acad. Sci. USA 83, 6766-6770 (1986
35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993
36. Howey, D. C., Bowsher, R. R., Brunelle, R. L., & Woodworth, J. R. [Lys (B28), Pro (B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43, 396-402 (1994
37. Torlone, E., et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys (B28), Pro (B29)] in IDDM. Diabetologia 37, 713-720 (1994
38. Anderson, J. H., et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin. Ther. 19, 62-72 (1997
39. Home, P., Lindholm, A., & Riis, A. Insulin aspart versus human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. 17, 762-770 (2000
40. Home, P. D., Lindholm, A., Hylleberg, B., & Round, P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 21, 1904-1909 (1998
41. Brange, J., et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 333, 679-682 (1988
42. Becker, R. H., & Frick, A. D. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin. Pharmacokinet. 47, 7-20 (2008
43. Becker, R., Frick, A., Burger, F., Potgieter, J., & Scholtz, H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp. Clin. Endocrinol. Diabetes 113, 435-443 (2005
44. Dreyer, M., et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm. Metab. Res. 37, 702-707 (2005
45. Owens, D. R., Matfin, G., & Monnier, L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab. Res. Rev. 30, 104-119 (2014
46. Zinman, B. Newer insulin analogs: advances in basal insulin replacement. Diabetes Obes. Metab. 15, 6-10 (2013
47. Oakley, W., Hill, D., & Oakley, N. Combined use of regular and crystalline protamine (NPH) insulins in the treatment of severe diabetes. Diabetes 15, 219-222 (1966
48. Hilgenfeld, R., et al. Controlling insulin bioavailability by crystal contact engineering. Diabetologia 35 (Suppl.), A193 (1992
49. Rosenstock, J., et al. Basal insulin therapy in type 2 diabetes 28 week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24, 631-636 (2001
50. Guthrie, R. Is there a need for a better basal insulin? Clinical Diabetes 19, 66-70 (2001
51. Jørgensen, S., Vaag, A., Langkjær, L., Hougaard, P., & Markussen, J. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. BMJ 299, 415-419 (1989
52. Myers, S., et al. W99 S32 a soluble, basal insulin analog. Diabetologia 38 (suppl. 1), A4 (1995
53. Hoeg-Jensen, T. in Peptide and Protein Design for Biopharmaceutical Applications (ed K. J., Jensen) 249-286 (Wiley, 2009
54. Havelund, S., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21, 1498-1504 (2004
55. Hermansen, K., et al. 26 week, randomized, parallel, treat to target trial comparing insulin detemir with NPH insulin as add on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29, 1269-1274 (2006
56. Hu, Y., et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β cell function in subjects with long-term remission. Diabetes Care 34, 1848-1853 (2011
57. Retnakaran, R., & Zinman, B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function. Diabetes Obes. Metab. 14, 161-166 (2011
58. DCCT. Hypoglycemia in the diabetes control and complications trial. Diabetes 46, 271-286 (1997
59. Vora, J., & Heise, T. Variability of glucose cowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes. Metab. 15, 701-712 (2013
60. Barag, S. H. Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence. J. Am. Osteopath. Assoc. 111, S13-S19 (2011
61. AntriaBio. Corporation Presentation, Q1 2015. AntriaBio Inc. [online], http://ir.stockpr.com/antriabio/(2015
62. Ascendis Pharma. TransCon Diabetes Program. Ascendis Pharma Inc [online], http://ascendispharma. com/product-pipeline/transcon-diabetes-program/(2010
63. Sanofi-Aventis. Sanofi-Aventis acquires from Ascendis Pharma worldwide rights on drug-delivery technology in diabetes and related disorders. Sanofi [online], http://www.sanofi.se/l/se/sv/layout. jsp'cnt=9035046E-F46C-4E3B-B03E-CDAC6E08FD75 (2010
64. Hwang, S. Y., et al. Novel very long-acting insulin analog (HM12470) with potential for once-weekly dosing has a favorable PK, PD and mitogenic profile. American Diabetes Association's 74th Scientific Sessions [online], http://app.core-apps.com/tristar-ada14/abstract/e3048dedfd3d5fbcc516bc863839d40b (2014
65. Huh, Y., et al. Use of PKPD model to design and analyze results of a euglycemic clamp study for a very long-acting insulin analogue HM12470. American Diabetes Association's 75th Scientific Sessions [online], app.core-apps.com/tristar-ada15/abstract/1678f29f2a56ce35baedcc25f3927f61 (2015
66. Arnold, S., Jowett, J., & Ballance, J. Synergistic action of PE0139, a super-long-acting basal insulin, & PB1023 a weekly GLP1 receptor agonist. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393cf39e4 (2015
67. Jowett, J., & Woods, C. Therapeutic agents comprising insulin amino acid sequences. US Patent 20130150291 (2012
68. Marquez, F., et al. PE0139, the first recombinant fully human monomeric super-long-acting basal insulin to display a sustained nearly peakless insulin profile following a single subcutaneous dose in subjects with T2DM supporting weekly dosing. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f3934c37af (2015
69. Novo Nordisk. Novo Nordisk Receives FDA Approval for Tresiba® (insulin degludec injection) for Adults with Type 1 and Type 2 Diabetes. Novo Nordisk [online], http://press.novonordisk-us.com/2015-09-25-Novo-Nordisk-Receives-FDA-Approval-for-Tresiba-insulin-degludec-injection-for-Adults-with-Type-1-and-Type-2-Diabetes (2015
70. Hartman, M. L., et al. Liver enzyme results from 7 basal insulin peglispro (BIL) clinical trials in T1D and T2D. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393d4a39e (2015
71. Rosenstock, J., et al. better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 36, 522-528 (2013
72. Cobry, E., et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol. Ther. 12, 173-177 (2010
73. Shah, V. N., Shoskes, A., Tawfik, B., & Garg, S. K. Closed-loop system in the management of diabetes: past, present, and future. Diabetes Technol. Ther. 16, 477-490 (2014
74. Zhang, Z., Tang, Y., Yao, S., Zhu, S., & Feng, Y. Protein engineering of insulin: two novel fast-acting insulins [B16Ala] insulin and [B26Ala] insulin. Sci. China C Life Sci. 46, 474-480 (2003
75. Weiss, M. Insulin analogues with chlorinated amino acids, US Patent 9079975 (2015
76. Weiss, M. Halogen-stabilized insulin. US Patent 8921313 (2014
77. Krasner, A., et al. Safety and efficacy of ultra-rapid-acting human insulin formulation BIOD 123 in patients with type 1 diabetes. American Diabetes Association's 74th Scientific Sessions [online], http://app.core-apps.com/tristar-ada14/abstract/e3048dedfd3d5fbcc516bc8638402331 (2014
78. Andersen, G., et al. Ultra-rapid BioChaperone insulin lispro (BC LIS): linear dose-response and faster absorption than insulin Lispro (LIS). Diabetologia 58 (Suppl 1), S449-S449 (2015
79. Hua, Q. X., et al. Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications. J. Biol. Chem. 283, 14703-14716 (2008
80. Duttaroy, A., et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54, 251-258 (2005
81. DiMarchi, R. D., et al. Single-chain insulin agonists exhibiting high activity at the insulin receptor. US Patent 8940860 (2011
82. Kaur, Z. P., et al. Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker. ACS Chem. Biol. 8, 1822-1829 (2013
83. Andersen, A. S., et al. Backbone cyclic insulin. J. Pept. Sci. 16, 473-479 (2010
84. Stowell, M. H., & Plam, M. Chemically and thermodynamically stable insulin analogues and improved methods for their production. US Patent 9006176 (2015
85. Wang, Y., Shao, J., Zaro, J. L., & Shen, W. C. Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production. Diabetes 63, 1779-1788 (2014
86. Phillips, N. B., Whittaker, J., Ismail-Beigi, F., & Weiss, M. A. Insulin fibrillation and protein design: topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir. J. Diabetes Sci. Technol. 6, 277-288 (2012
87. Polonsky, K. S., & Rubenstein, A. H. C peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33, 486-494 (1984
88. Eaton, R. P., Allen, R. C., & Schade, D. S. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J. Clin. Endocrinol. Metab. 56, 1294-1300 (1983
89. Meier, J. J., Veldhuis, J. D., & Butler, P. C. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 54, 1649-1656 (2005
90. Meyer, C., Woerle, H. J., Dostou, J. M., Welle, S. L., & Gerich, J. E. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 287, E1049-E1056 (2004
91. Canavan, J., Flecknell, P., New, J., Alberti, K., & Home, P. The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM. Diabetologia 40, 1125-1134 (1997
92. Sekigami, T., et al. Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artificial endocrine pancreas. J. Artif. Organs 7, 91-100 (2004
93. Herring, R., Jones, R. H., & Russell-Jones, D. L. Hepatoselectivity and the evolution of insulin. Diabetes Obes. Metab. 16, 1-8 (2014
94. Edgerton, D. S., et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J. Clin. Invest. 116, 521-527 (2006
95. Tompkins, C. V., Brandenburg, D., Jones, R. H., & Sönksen, P. H. Mechanism of action of insulin and insulin analogues. Diabetologia 20, 94-101 (1981
96. Glauber, H. S., et al. In vivo deactivation of proinsulin action on glucose disposal and hepatic glucose production in normal man. Diabetes 35, 311-317 (1986
97. Smeeton, F., et al. Differential effects of insulin detemir and neutral protamine hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Diabetologia 52, 2317-2323 (2009
98. Henry, R. R., et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 37, 2609-2615 (2014
99. Shojaee-Moradie, F., et al. Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 23, 1124-1129 (2000
100. Seino, S., & Bell, G. I. Alternative splicing of human insulin receptor messenger RNA. Biochem. Biophys. Res. Commun. 159, 312-316 (1989
101. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623 (2009
102. Mosthaf, L., et al. Journal 9, 2409 (1990
103. Moller, D. E., Yokota, A., Caro, J. F., & Flier, J. S. Tissue specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol. Endocrinol. 3, 1263-1269 (1989
104. Leibiger, B., et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic β cells. Mol. Cell 7, 559-570 (2001
105. Sara, G. V., et al. Receptor-isoform-selective insulin analogues give tissue-preferential effects. Biochem. J. 440, 301-308 (2011
106. Siddle, K. Signalling by insulin, & IGF receptors: supporting acts and new players. J. Mol. Endocrinol. 47, R1-R10 (2011
107. Owens, D. R., Zinman, B., & Bolli, G. Alternative routes of insulin delivery. Diabet. Med. 20, 886-898 (2003
108. Khafagy, E. S., Morishita, M., Onuki, Y., & Takayama, K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev. 59, 1521-1546 (2007
109. Mack, G. S. Pfizer dumps Exubera. Nat. Biotechnol. 25, 1331-1332 (2007
110. Iyer, H., Khedkar, A., & Verma, M. Oral insulin - A review of current status. Diabetes Obes. Metab. 12, 179-185 (2010
111. Heinemann, L. Insulin pens and new ways of insulin delivery. Diabetes Technol. Ther. 16, S44-S55 (2014
112. Kling, J. Sanofi to propel inhalable insulin Afrezza into market. Nat. Biotechnol. 32, 851-852 (2014
113. Neumiller, J., & Campbell, R. K. Technosphere® Insulin. BioDrugs 24, 165-172 (2010
114. Rosenstock, J., et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 375, 2244-2253 (2010
115. MannKind Corporation. MannKind Corporation announces termination of license and collaboration agreement with Sanofi. MannKind Corpoartion [online], http://investors.mannkindcorp.com/releasedetail.cfm'ReleaseID=948810 (2016
116. Eldor, R., Arbit, E., Corcos, A., & Kidron, M. Glucose-reducing effect of the ORMD 0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PloS ONE 8, e59524 (2013
117. Novo Nordisk. OI338GT (NN1953) Phase II trial. Novo Nordisk [online], http://www.novonordisk.com/rnd/pipelinedetails.1454357205907-11.html (2016
118. Novo Nordisk. Financial report for the period 1 January 2014 to 31 March 2014. Novo Nordisk Company Announcement [online], https://www. novonordisk.com/bin/getPDF.1781915.pdf (2014
119. Wu, Q., Wang, L., Yu, H., Wang, J., & Chen, Z. Organization of glucose-responsive systems and their properties. Chem. Rev. 111, 7855-7875 (2011
120. Wu, W., & Zhou, S. Responsive materials for self-regulated insulin delivery. Macromol. Biosci 13, 1464-1477 (2013
121. Merck, & Co., Inc. Merck to Acquire SmartCells, Inc. Merck Press Releases [online], http://www.merck.com/licensing/our-partnership/SmartCells-partnership.html (2010
122. Zion, T. C., & Lancaster, T. M. Crystalline insulin-conjugates. US Patent 8906850 (2010
123. Chou, D. H. C., et al. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc. Natl Acad. Sci. USA 112, 2401-2406 (2015
124. Hoeg-Jensen, T., Havelund, S., Nielsen, P. K., & Markussen, J. Reversible insulin self-assembly under carbohydrate control. J. Am. Chem. Soc. 127, 6158-6159 (2005
125. Hoeg-Jensen, T., et al. Glucose dependent release of insulin from glucose sensing insulin derivatives. US Patent 316999 (2008
126. Hoeg-Jensen, T., Jakobsen, P., Sensfuss, U., Fledelius, C., & Ribel-Madsen, U. Insulin derivatives. US Patent WO2011000823 (2010
127. Garg, S. K. The role of basal insulin and glucagon-like peptide 1 agonists in the therapeutic management of type 2 diabetes - A comprehensive review. Diabetes Technol. Ther.12, 11-24 (2010
128. Vora, J. Combining incretin-based therapies with insulin realizing the potential in type 2 diabetes. Diabetes Care 36, S226-S232 (2013
129. Balena, R., Hensley, I., Miller, S., & Barnett, A. Combination therapy with GLP 1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes. Metab. 15, 485-502 (2013
130. Holst, J., & Vilsbøll, T. Combining GLP 1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes. Metab. 15, 3-14 (2013
131. Baggio, L. L., & Drucker, D. J. Biology of incretins: GLP 1 and GIP. Gastroenterology 132, 2131-2157 (2007
132. Mathieu, C., et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes. Metab. 16, 636-644 (2014
133. Rosenstock, J., et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 37, 2317-2325 (2014
134. Gough, S. One-year efficacy and safety of IDegLira in patients with type 2 diabetes. American Diabetes Association's 74th Scientific Sessions [online], http://app.core-apps.com/tristar-ada14/abstract/e3048dedfd3d5fbcc516bc8638a6c9c1 (2014
135. Vilsbøll, T., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide -regardless of etiology and phenotype. J. Clin. Endocrinol. Metab. 88, 4897-4903 (2003
136. Miyawaki, K., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Medicine 8, 738-742 (2002
137. Kim, S. J., et al. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS ONE 7, e40156 (2012
138. Kerr, B. D., et al. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem. Pharmacol. 78, 1008-1016 (2009
139. Gault, V. A., Porter, D. W., Irwin, N., & Flatt, P. R. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP (1-30) and GIP (1-42) in high-fat fed mice. J. Endocrinol. 208, 265-271 (2011
140. Finan, B., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl Med. 5, 209ra151 (2013
141. Baeshen, N. A., et al. Cell factories for insulin production. Microb. Cell Fact. 13, 141 (2014
142. Keasling, J. D., Mendoza, A., & Baran, P. S. Synthesis: a constructive debate. Nature 492, 188-189 (2012
143. Liu, F., Luo, E. Y., Flora, D. B., & Mayer, J. P. Concise synthetic routes to human insulin. Org. Lett. 15, 960-963 (2013
144. Liu, F., Luo, E. Y., Flora, D. B., & Mezo, A. R. A. Synthetic route to human insulin using isoacyl peptides. Angew. Chem. Int. Ed. Engl. 53, 3983-3987 (2014
145. Zaykov, A. N., Mayer, J. P., Gelfanov, V. M., & DiMarchi, R. D. Chemical synthesis of insulin analogs through a novel precursor. ACS Chem. Biol. 9, 683-691 (2013
146. Walsh, G. Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol. 67, 151-159 (2005
147. Avital-Shmilovici, M., et al. Fully convergent chemical synthesis of ester insulin: determination of the high resolution X-ray structure by racemic protein crystallography. J. Am. Chem. Soc. 135, 3173-3185 (2013
148. Sohma, Y., Hua, Q. X., Whittaker, J., Weiss, M. A., & Kent, S. B. H. Design and folding of [GluA4(OβThrB30)] Insulin (ester insulin): a minimal proinsulin surrogate that can be chemically converted into human insulin. Angew. Chem. Int. Ed. Engl. 49, 5489-5493 (2010
149. Tofteng, A. P., Jensen, K. J., Schäffer, L., & Hoeg-Jensen, T. Total synthesis of desB30 insulin analogues by biomimetic folding of single-chain precursors. ChemBioChem 9, 2989-2996 (2008
150. Qiang, G., et al. Identification of a small molecular insulin receptor agonist with potent antidiabetes activity. Diabetes 63, 1394-1409 (2014
151. Bhaskar, V., et al. Fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 61, 1263-1271 (2012
152. Bedinger, D. H., Goldfine, I. D., Corbin, J. A., Roell, M. K., & Adams, S. H. Differential pathway coupling of the activated insulin receptor drives signaling selectivity by XMetA, an allosteric partial agonist antibody. J. Pharmacol. Exp. Ther. 353, 35-43 (2015
153. Schäffer, L., et al. Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc. Natl Acad. Sci. USA 100, 4435-4439 (2003
154. Knudsen, L., et al. Agonism and antagonism at the insulin receptor. PloS ONE 7, e51972 (2012
155. Jensen, M., Hansen, B., De Meyts, P., Schäffer, L., & Ursø, B. Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J. Biol. Chem. 282, 35179-35186 (2007
156. Yunn, N. O., et al. Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation. Nucleic Acids Res. 43, 7688-7701 (2015
157. Mameli, C., et al. 7 year follow up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes. Acta Diabetol. 51, 205-210 (2014
158. Pickup, J. C. Diabetes: insulin pump therapy for type 2 diabetes mellitus. Nat. Rev. Endocrinology 10, 647-649 (2014
159. Pickup, J. C. Insulin-pump therapy for type 1 diabetes mellitus. N. Engl. J. Med. 366, 1616-1624 (2012
160. Bouwens, L., Houbracken, I., & Mfopou, J. K. The use of stem cells for pancreatic regeneration in diabetes mellitus. Nat. Rev. Endocrinology 9, 598-606 (2013
161. Pagliuca, F. W., et al. Generation of functional human pancreatic β cells in vitro. Cell 159, 428-439 (2014
162. Goh, S. K., et al. Perfusion-decellularized pancreas as a natural 3D scaffold for pancreatic tissue and whole organ engineering. Biomaterials 34, 6760-6772 (2013
163. Brethauer, S. A., et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann. Surg. 258, 628-636 (2013
164. Sjöström, L., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004
165. Schauer, P. R., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366, 1567-1576 (2012
166. Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. Anti-obesity drugs: past, present and future. Dis. Model. Mech. 5, 621-626 (2012
167. Xu, J., et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models -association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105-E1114 (2009
168. Holland, W. L., et al. An FGF21 adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797 (2013
169. Denroche, H. C., Huynh, F. K., & Kieffer, T. J. The role of leptin in glucose homeostasis. J. Diabetes Investig. 3, 115-129 (2012
170. Fani, L., Bak, S., Delhanty, P., van Rossum, E., & van den Akker, E. The melanocortin 4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int. Journal Obes. 38, 163-169 (2014
171. Pearson, T. L. Practical aspects of insulin pen devices. J. Diabetes Sci. Technol. 4, 522-531 (2010
172. Zijlstra, E., Heinemann, L., & Plum-Mörschel, L. Oral insulin reloaded a structured approach. J. Diabetes Sci. Technol. 8, 458-465 (2014
173. Kidron, M., Neutel, J., & Arbit, E. Preprandial oral insulin (ORMD 0801) reduces rapid-acting insulin requirements and fasting glucose levels in T1DM patients (poster). American Diabetes Association's 75th Scientific Sessions [online], http://www.oramed.com/wp-content/uploads/2015/06/ADA-poster-2015.pdf (2015
174. Geiss, L. S., Herman, W. H., & Smith, P. J. in Diabetes in America (ed R. Aubert) 233-255 (DIANE Publishing, 1995
175. Jonassen, I., et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104-2114 (2012
176. Wang, F., Surh, J., & Kaur, M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Meta. Synd. Obes. 5, 191-204 (2012
177. Sorli, C., et al. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of Phase IIIa trials. Drugs Aging 30, 1009-1018 (2013
178. Birkeland, K. I., et al. Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. Diabetologia 54 (Suppl. 1), 542 (2011
179. Dorey, E. FDA dashes Novo's hopes. Nat. Biotechnol. 31, 266-266 (2013
180. Sinha, V. P., et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J.Clin. Pharmacol. 54, 792-799 (2014
181. Bergenstal, R. M., et al. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. Diabetes Care 37, 659-665 (2013
182. Jacober, S. J., et al. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes Obes. Metab. 16, 351-356 (2014
183. Wigley, F. M., Londono, J. H., Wood, S. H., Shipp, J. C., & Waldman, R. H. Insulin across respiratory mucosae by aerosol delivery. Diabetes 20, 552-556 (1971
184. Eli Lilly and Company. Lilly Ends Basal Insulin Peglispro Development Program. Lilly Investor Press Release [online], https://investor.lilly.com/releasedetail. cfm'releaseid=945541 (2014
185. Buse, J. B., et al. Superior HbA1c reduction with basal insulin peglispro (BIL) versus insulin glargine (GL) alone or with oral antihyperglycemic medications (OAMs) in T2D patients (Pts) previously treated with basal insulin: IMAGINE 5. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393d4a01b (2015
186. Blevins, T., et al. Superior HbA1c reduction with basal insulin peglispro (BIL) versus insulin glargine (GL) and preprandial insulin lispro in a double blind study in patients (pts) with type 2 diabetes (T2D): IMAGINE 4. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393d487b1 (2015
187. Bergenstal, R. M., et al. Superior reduction of HbA1c in a double-blind, randomized study of basal insulin peglispro (BIL) versus insulin glargine (GL) in patients (pts) with T1D: IMAGINE 3. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393d4a470 (2015
188. Hansen, R., et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes 61, A228 (2012
189. Zijlstra, E., et al. Dance 501 inhaled human insulin has a dose-linear response and similar within-subject variability as rapid-acting insulin lispro. American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393ceba3d (2015
190. Smith, N. B., et al. Ultrasound-mediated transdermal transport of insulin in vitro through human skin using novel transducer designs. Ultrasound Med. Biol. 29, 311-317 (2003
191. Transdermal Specialties Inc. The U-Strip -Insulin Patch. Transdermal Specialties [online], http://www.transdermalspecialties.com/u-strip-patch.html (2015
192. Gough, S. C. L., et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a Phase 3, open-label, randomised, 26 week, treat to target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2, 885-893 (2014
193. Rosenstock, J., et al. Improved glucose control without increased hypoglycemia risk at any level of HbA1c reduction with insulin glargine/lixisenatide fixed-ratio combination (LixiLan) versus insulin glargine alone both added on to metformin in type 2 diabetes (T2DM). American Diabetes Association's 75th Scientific Sessions [online], http://app.core-apps.com/tristar-ada15/abstract/160858d53930b598d64b10f393cf410d (2015
194. Sanofi. FDA accepts Sanofi new drug application for once-daily fixed-ratio combination of insulin glargine and lixisenatide. Sanofi [online], http://www.news.sanofi.us/2016-02-22-FDA-Accepts-Sanofi-New-Drug-Application-for-Once-Daily-Fixed-Ratio-Combination-of-Insulin-Glargine-and-Lixisenatide (2016
195. Onishi, Y., Ono, Y., Rabøl, R., Endahl, L., & Nakamura, S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes. Metab. 15, 826-832 (2013
196. Fulcher, G. R., et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat to target trial. Diabetes Care 37, 2084-2090 (2014
197. Hirsch, I. B., et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes. A 26 week, phase 3, randomized, open-label, treat to target trial. Diabetes Care 35, 2174-2181 (2012